Current problems in cancer. Case reports最新文献

Breast cancer (BC) is a complex and heterogeneous disease including different biological subtypes. This results in molecular and phenotypic heterogeneity within the BC. Stratification of tumors contributed to achieving better outcome in terms of response to therapy and overall survival. Little is known about the features of clonal heterogeneity in different lesion in BC patient. We reported a case of a 52-year-old woman who was diagnosed with luminal B (HER2−) BC and accepted chemotherapy. She achieved partial response based on RECIST 1.1 criteria. However, progressive disease (PD) was then identified with multiple subtypes including luminal B and triple-negative breast cancer (TNBC). Next-generation sequencing (NGS) technologies showed that the different regions of diseased tissue were originated from same clonal genes. We also demonstrated the clonal heterogeneity and gene characterization between lesions of luminal B and TNBC. The patient archived complete remission (CR) with a clear beneficial outcome from immunotherapy treatment. In addition, tumour mutational burden (TMB) and DNA damage repair (DDR) pathway were considered as potential biomarkers for better prediction of tumor immunotherapy efficacy.

Airway blockage frequently occurs in advanced lung cancer patients, leading to breathing difficulties and oxygen deprivation. This severely impacts patients' quality of life and can even result in death. Bronchial stent insertion effectively alleviates these symptoms and is often performed with intravenous general anesthesia. Nevertheless, during anesthesia and the procedure, inadequate ventilation can lead to severe oxygen deficiency and subsequent complications. There is an urgent need for a safe and efficient intraoperative ventilation strategy to maintain sufficient oxygen levels and reduce the risk of oxygen deficiency. We present a case of successful bronchial stent placement using high-flow nasal cannula (HFNC) in conjunction with intravenous general anesthesia. The patient, a 64-year-old male with a one-year history of right peripheral lung cancer, sought treatment for persistent cough and breathing difficulties. Chest X-rays upon admission revealed a substantial increase in the size of the anterior segment of the right upper lung lobe, likely due to peripheral lung cancer complicated by obstructive pneumonia. To address the patient's airway compression symptoms, we proposed "bronchoscopic tracheal stent insertion." The patient exhibited an ejection fraction of 45% on cardiac ultrasound, had limited physical activity tolerance, grade III heart function, severe airway constriction, and maintained oxygen saturation (SPO₂) levels between 85% and 88%. We successfully performed the procedure using HFNC in combination with intravenous general anesthesia, resulting in a significant improvement in airway compression symptoms. In this case, it was found that HFNC could be used as a new non-invasive respiratory support therapy for bronchial stent implantation under intravenous general anesthesia to reduce the occurrence of intraoperative hypoxemia.

Background

This case report aims to describe an adverse reaction following intra-arterial melphalan chemotherapy in a 48-year-old female patient with choroidal melanoma. The chemotherapy was part of a phase I clinical trial (MELCOM Study - ClinicalTrials.gov ID: NCT05893654), designed to evaluate its efficacy as a bridge to Ru-106 brachytherapy for treating large uveal melanomas. This is the first reported case of a cutaneous reaction to melphalan in an adult patient.

Observations

Upon administration of melphalan, the patient developed an erythematous periorbital skin lesion three days post-treatment. The lesion evolved into a hyperchromic brownish macule that later disappeared spontaneously.

Conclusions and Importance

While melphalan successfully reduced the tumor dimensions, making the patient eligible for subsequent Ru-106 brachytherapy, it led to a cutaneous reaction previously reported only in pediatric patients. Despite this aesthetic complication, the therapy was effective in tumor reduction, highlighting the need for further studies to assess the risk-benefit profile of intra-arterial melphalan chemotherapy in adult populations.

We report the case of a 48-year-old female with a history of tubal ligation who presented to her PCP with altered mental status and back pain. Inpatient workup revealed multiple myeloma, and treatment with bortezomib and dexamethasone was initiated. Due to teratogenicity on lenalidomide, a pre-treatment urine pregnancy test was performed and returned positive. She denied sexual activity and had no history of germ cell tumor. While urine hCG remained low positive for three tests, her serum hCG remained normal (<5 mIU/mL). The uncertainty in pregnancy testing caused a delay in full-dose induction therapy. With two cycles of bortezomib and dexamethasone, her M-Spike only dropped from 4.8 to 2.9 g/dL. Ultimately urine hCG normalized, and she was started on lenalidomide with cycle number three. With the addition of lenalidomide, after two cycles, her M-Spike disappeared, and bone marrow biopsy showed complete resolution of plasma cell dyscrasia. The phenomenon of positive hCG testing in multiple myeloma is discussed, highlighting the importance of provider and patient awareness in the setting of a non-gravid woman to prevent a disruption of standard of care treatment and patient distress.

Parathyroid carcinoma is one of the rare causes of primary hyperparathyroidism, comprising less than 1 % of its cases. Diagnosing parathyroid carcinoma typically requires a comprehensive evaluation using clinical, histological, and radiological methods. Primary hyperparathyroidism secondary to parathyroid carcinoma often presents with hypercalcemia, bone abnormalities, and renal stones. Brown tumours, a rare and late manifestation of hyperparathyroidism, signify the final stage in bone remodelling, and they can be easily mistaken for bony metastases, which highlights the importance of distinguishing between them to ensure appropriate management and avoid unnecessary treatment. Due to the rarity of parathyroid carcinoma, there is currently no standardized staging system or specific guidelines for its management. Consequently, the involvement of a multidisciplinary team has become crucial in addressing this disease. Surgery is considered the primary treatment approach, while the role of adjuvant radiotherapy and chemotherapy remains controversial. With ongoing research, the treatment landscape for parathyroid carcinoma may evolve, offering new hope for improved outcomes and quality of life for affected individuals.

Thymoma and thymic carcinomas are rare tumors with limited therapeutic options for platinum-refractory cases. Recent studies have shown positive response rates in anti-angiogenic multi-kinase inhibitors (MKI) such as lenvatinib and sunitinib and immune checkpoint inhibitors including pembrolizumab, though they have yet to be tested in combination. Here, we present a case of a patient with heavily pre-treated PD-L1 negative metastatic thymic carcinoma and no targetable mutations treated with combination lenvatinib and pembrolizumab following initial response then progression from lenvatinib monotherapy. He had a partial response with decreased tumor burden in the liver with lenvatinib monotherapy and then in the lungs with combination therapy. Treatment was continued and he continues have clinical benefit with stable disease at 9 months with minimal toxicities. This case is one of the first reported clinical evidence for MKI and immunotherapy in combination as a promising second-line approach for thymic carcinomas.

Low-grade adenosquamous carcinoma (LGASC) is a rare variant of metaplastic breast carcinoma that consists of glandular and squamous elements in a spindle cell background. They lack distinctive imaging features and overlap with other breast neoplasm characteristics, posing a diagnostic challenge. We present the case of a 60-year-old woman with metachronous bilateral invasive breast carcinoma (MBBC). The mastectomy specimens of her left breast carcinoma revealed nests of squamous- appearing cells and “comma” glandular structures on a microscopic level. Comprehensive immunohistochemical examination of ER, PR, Her-2, p63, and CK7 CK5/6 confirmed the diagnosis of LGASC. Unlike other invasive breast carcinomas, LGASC have an indolent course and favorable prognosis. Eight years after surgery, she was diagnosed with a non-specific type of invasive breast carcinoma of the right breast via imaging, core needle biopsy and immunohistochemistry. This was a rare case of MBBC that has not been previously reported. Therefore, we report and review the relevant literature to raise awareness of this disease.

Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare type of T-cell lymphoma of the gastrointestinal tract that presents an aggressive course. Previously, this entity was named type II T-cell lymphoma associated with enteropathy. However, in later years it was classified as a different entity due to its particular characteristics. This neoplasm usually affects the jejunum and ileum and usually has a clinical presentation with intestinal perforation, intestinal obstruction or bleeding. Its diagnosis requires histopathological evaluation and differentiation from other types of T cell lymphomas that affect the intestine. Its prognosis is usually very poor and therapeutic options are limited and are based on induction chemotherapy followed by autologous bone marrow transplant. This article presents the first case of MEITL in Peru, in an elderly patient who presented at hospital emergency with intestinal perforation and that presented multiple relapses of the neoplasm.

Adenoid cystic carcinoma (ACC) is a rare type of breast cancer, and predominant adenoid cystic carcinomas are low grade and triple-negative by histology. Unlike other triple-negative breast carcinomas, ACC of the breast generally have a low propensity for recurrence and metastasis, with complete surgical excision alone being curative in most circumstances in early-stage disease. Here, we presents a case study detailing the clinical course of a 32-year-old female patient diagnosed with ACC of the breast. We emphasized the efficacy of standardized treatment protocols and highlighted recent advancements in research pertaining to this uncommon malignancy.